H.C. Wainwright analyst Oren Livnat reiterated a Buy rating on Agile Therapeutics (AGRX – Research Report) today and set a price target of $3.00. The company’s shares closed yesterday at $0.20.
According to TipRanks, Livnat is an analyst with an average return of -3.9% and a 39.72% success rate. Livnat covers the Healthcare sector, focusing on stocks such as Avadel Pharmaceuticals, Jazz Pharmaceuticals, and Pacira Pharmaceuticals.
Currently, the analyst consensus on Agile Therapeutics is a Moderate Buy with an average price target of $2.00.
See the top stocks recommended by analysts >>
The company has a one-year high of $21.34 and a one-year low of $0.18. Currently, Agile Therapeutics has an average volume of 819.8K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Agile Therapeutics, Inc. is a healthcare company, which engages in the development and commercialization of transdermal patch. Its lead product candidate, Twirla, also known as AG200-15, is an investigational low-dose, non-daily prescription contraceptive. The company was founded by Chien Te Yen on December 22, 1997 and is headquartered in Princeton, NJ.
Read More on AGRX:
